Leucovorin wins rare-disease approval without trials as Epstein-linked investor quietly revives biotech career
TL;DR Summary
FDA approves leucovorin for a rare disorder without new trial data, while STAT reports that Boris Nikolic—once linked to Jeffrey Epstein—was quietly helped by investor Alexis Borisy to stage a biotech comeback, and notes ongoing probes into FDA drug-rejection decisions.
- FDA approves leucovorin for rare disorder without trial data statnews.com
- ‘Betrayed’: Families are dealing with dashed hopes after pivot on autism treatment CNN
- FDA finds little evidence that the generic drug leucovorin can help people with autism PBS
- FDA backs away from RFK Jr.’s claims about drug’s promise for autism patients Politico
- FDA scales back vision for drug it touted as possible treatment for autism The Washington Post
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
2 min
vs 2 min read
Condensed
90%
385 → 40 words
Want the full story? Read the original article
Read on statnews.com